Clinical trials: Keratoconjunctivitis
Keratoconjunctivitis Sicca
Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
This is a randomized, double-masked, vehicle-controlled study of the safety and efficacy of OTX-101 (0.09% cyclosporine nanomicellar solution) in the treatment of keratoconjunctivitis sicca to be conducted at approximately 50…
- Trial name
- Emerald (NCT02688556)
- Testing
- cyclosporine, vehicle of OTX-101
- Where
- 3 sites in United States
- Volunteers
- 745 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Keratoconjunctivitis Sicca
A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)
The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.
- Trial name
- NCT02121301
- Testing
- Low Dose 0.155µg/mL SkQ1 ophthalmic solution, High Dose 1.55µg/mL SkQ1 ophthalmic solution
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Mitotech, SA
Keratoconjunctivitis Sicca
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
The purpose of this study is to determine whether 0.2% and 0.5% R348 Ophthalmic Solutions are safe and effective in the treatment of Patients with Keratoconjunctivitis Sicca.
- Trial name
- DROPS (NCT01900249)
- Testing
- R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%
- Where
- 20 sites in United States
- Volunteers
- 204 people
- Sponsor
- Rigel Pharmaceuticals
Keratoconjunctivitis Sicca, Dry Eye Disease
Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)
The purpose of the study is to evaluate the efficacy of SAR 1118 Ophthalmic Solution (5.0%) compared to placebo in the treatment of Dry Eye.
- Trial name
- OPUS-1 (NCT01421498)
- Testing
- Lifitegrast
- Where
- 13 sites in United States
- Volunteers
- 588 people
- Sponsor
- Shire
Dry Eye, Dry Eye Syndromes
Tear Production by Nasal Neurostimulation Compared to Active Control
This crossover design study evaluates the effectiveness of the Oculeve Intranasal Neurostimulator comparing the effect of intranasal (active) versus extranasal (control) stimulation on tear production as measured by the Jones…
- Conditions
- Dry Eye, Dry Eye Syndromes, Keratoconjunctivitis Sicca
- Trial name
- NCT02970799
- Testing
- Intranasal Neurostimulator
- Volunteers
- 27 people
- Sponsor
- Oculeve, Inc.
Keratoconjunctivitis Sicca
Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
This is a Phase 2, randomized, double-masked, placebo-controlled, parallel-group study in adult males and females, aged 18 years and over, with a diagnosis of moderate-to-severe keratoconjunctivitis sicca (KCS).
- Trial name
- NCT00349466
- Testing
- CF101
- Where
- 3 sites in Israel
- Volunteers
- 80 people
- Sponsor
- Can-Fite BioPharma
Conjunctivitis, Vernal
Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)
The primary objective of this study is: To assess the efficacy of Nova22007, a cyclosporine A (CsA), 0.05% and 0.1% versus vehicle in patients with vernal keratoconjunctivitis (VKC) after a 4-week treatment period.
- Trial name
- NCT00328653
- Testing
- Cyclosporine NOVA22007 0.05%, Cyclosporine NOVA22007 0.1%, Vehicle
- Where
- France
- Volunteers
- 118 people
- Sponsor
- Santen SAS
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye
This study will evaluate the safety and efficacy of OPTIVE® MD for ocular surface integrity in symptomatic dry eye condition in absence of obvious eye-lid inflammation.
- Trial name
- NCT00987727
- Testing
- carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD), sodium hyaluronate 0.18% (VISMED® Multi)
- Where
- France
- Volunteers
- 82 people
- Sponsor
- Allergan
Dry Eye Disease
Safety Study of Tivanisiran to Treat Dry Eye
This study will examine the safety of tivanisiran sodium eye drops versus vehicle when dosed once daily for 1 year in subjects with signs and symptoms of dry eye disease (DED).
- Trial name
- FYDES (NCT05310422)
- Testing
- Tivanisiran sodium ophthalmic solution, Vehicle ophthalmic solution
- Where
- 25 sites in United States
- Volunteers
- 301 people
- Sponsor
- Sylentis, S.A.
Vernal Keratoconjunctivitis
Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis
The objective of this study is to compare the efficacy of two different dosing regimen of NOVA22007 (1mg/ml ciclosporin/cyclosporine) eye drops, emulsion versus placebo (vehicle of the formulation) administered four times a day…
- Trial name
- NCT01751126
- Testing
- NOVA22007 ''Ciclosporin''
- Where
- 46 sites in United States, Croatia and 9 more
- Volunteers
- 169 people
- Sponsor
- Santen SAS
Dry Eye Syndrome
Study of SkQ1 as Treatment for Dry-eye Syndrome
The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.
- Trial name
- VISTA-1 (NCT03764735)
- Testing
- Low Dose - SkQ1, High dose - SkQ1, SkQ1 (Vehicle)
- Where
- 7 sites in United States
- Volunteers
- 452 people
- Sponsor
- Mitotech, SA
Keratoconjunctivitis Sicca
An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
This is a safety extension enrolling subjects participating in Study OTX-101-2016-001 (NCT02688556)
- Trial name
- NCT02845674
- Testing
- OTX-101 0.09%
- Volunteers
- 258 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Dry Eye Syndrome, Keratoconjunctivitis Sicca
Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator
The primary objective of this study is to evaluate acute tear production as measured by tear meniscus height (TMH) captured by optical coherence tomography (OCT) after single use of the Oculeve Intranasal Neurostimulator (OIN) in…
- Trial name
- NCT02798289
- Testing
- Oculeve Intranasal Neurostimulator
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Oculeve, Inc.
Dry Eye Disease
Effect of Cequa™ in Subjects With Dry Eye Disease
This is a Phase 4, multicenter, single arm, 12 week study in subjects with dry eye disease, which is inadequately controlled by cyclosporine 0.05% ophthalmic emulsion.
- Trial name
- NCT04357795
- Testing
- CequaTM (Cyclosporine 0.09%) ophthalmic solution
- Where
- 5 sites in United States
- Volunteers
- 135 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Keratoconjunctivitis Sicca
Trial of CF101 to Treat Patients With Dry Eye Disease
Eligible patients with dry eye will be treated with CF101 or placebo twice daily for 24 weeks. Disease activity will be assessed using evaluations of ocular surface integrity, tear production, and patient symptoms.
- Trial name
- NCT01235234
- Testing
- CF101
- Where
- Israel
- Volunteers
- 236 people
- Sponsor
- Can-Fite BioPharma
Dry Eye Syndrome, Keratoconjunctivitis Sicca
A Study to Evaluate the Safety and Effectiveness of Oculeve Intranasal Lacrimal Neurostimulator in Participants With Dry Eye Syndrome
The purpose of this study is to compare acute tear production produced by the Oculeve Intranasal Lacrimal Neurostimulator with two control devices in participants with aqueous tear deficiency.
- Trial name
- NCT02680158
- Testing
- Oculeve Intranasal, Oculeve Extranasal
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Oculeve, Inc.
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease.
- Trial name
- STRIDE 1 (NCT02813265)
- Testing
- KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
- Where
- 60 sites in United States
- Volunteers
- 918 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Limbal Stem Cell Deficiency
Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft
The main aim of the study is to determine the safety and feasibility of a cultivated autologous limbal epithelial cell (CALEC) transplantation in the treatment of limbal stem cell deficiency.
- Trial name
- CALEC (NCT02592330)
- Testing
- Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft, Cultivation of Limbal epithelial cells into a graft, CALEC Transplant
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Keratoconjunctivitis Sicca, Dry Eye Syndrome
Effects of Dry Eye Treatments on the Ocular Surface
The purpose of this study is to evaluate whether, in people with dry eye syndrome, over the counter artificial tears and the prescription eye drop, dexamethasone, change or effect the eyes response to a low humidity environment.
- Trial name
- NCT01797822
- Testing
- Dexamethasone, Artificial tear
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Keratoconjunctivitis Sicca
Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease
This study will evaluate the efficacy of cyclosporine ophthalmic solution vs. other non-prescription treatments in patients with dry eye disease.
- Trial name
- NCT00717418
- Testing
- cyclosporine ophthalmic emulsion 0.05%, artificial tears
- Where
- United States
- Volunteers
- 781 people
- Sponsor
- Allergan